Pulmonary administration of activated recombinant factor VII

Bratislava Medical Journal

Volumn 112, Issue 1, 2011, Pages 29-33

  Grochova, M ^a   Kalnasova, B ^a   Firment, J ^a   Olejarova, I ^b   Roland, R ^c   Lazurova, I ^a  

^a L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^b NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Slovakia)

^c Nephrology and Dialysis Center Fresenius   (Slovakia)

Author keywords

Activated recombinant factor VII; Diffuse alveolar haemorrhage; Glomerulonephritis associated with endocarditis; Intrapulmonary administration

Indexed keywords

BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; CASE REPORT; HUMAN; LUNG DISEASE; MALE; MIDDLE AGED;

FACTOR VIIA; HEMORRHAGE; HEMOSTATICS; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 78751617241     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Estella A, Jareńo A, Perez-Bello Fontaińa L. Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories. Cases J 2008; 1: 150. doi: 10.1186/1757-1626-1-150.
2. Franchini M, Manzato F, Salvagno LG, Lippi G. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systemic review. Lippincott Williams@Wilkins, 2007. Review article 589.
3. Hardy JF, Bélisle S, Van dar Linden P. Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials. Ann Thorac Surg 2008; 86: 1038-1048.
4. Heslett L, Nielsen JD, Levi M, Sengelov H, Johansson PI. Succesful pulmonary administration of activated recombinant factor VII in difuse alveolar hemorrhage. Crit Care 2006,10/R 177.
5. Mallarkey G, Brighton T, Thomson A, Kaye K, Seale P, Gazarian M. An Evaluation of Eptakog Alfa in nonhaemophiliac Conditions. Drugs 2008; 68 (12): 1665-1689.
6. Roberts HR, Monroe DM, Escobar MA: Current concepts in hemostasis. Anesthesiology 2004; 100: 722-730.
7. Terapeutické postupy pri život ohrozújiicom krvácaní. http://www.ssaim.sk/Terapeuticke_postupy_pri_ZOK.doc
8. Badour LM, Wilson WR, Bayer AS, et al. Infective endocarditis. Diagnosis, antimicrobial therapy and management of complications. Circulation 2005; 111: 3167-3184.
9. Conlon PJ, Jefferies F, Krigman HR, et al. Predictors of prognosis and risk of acute renal failure in bacterial endocarditis. Clin Nephrol 1988; 49: 96-101.
10. Majumdar A, Chowdhary S, Ferreira MA, et al. Renal pathological findings in infective endocarditis. Nephrol Dial Transplant 2000; 15: 1782-1787.
11. Tlevjeh IM, Steckelberg JM, Murad HS, et al. Temporal trends in infective endocarditis. J Amer Med Ass 2005; 293: 3022-3028.
12. Yoh K, Kobayashi M, Yamaguchi N, et al. Cytokines and T cell responses in superantigen-related glomerulonephritis following methicillin-resistant Staphylococcus aureus infection. Nephrol Dial Transplant 2000; 15: 1170-1174.